NCT01700985

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

Conditions

• Psoriasis
• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	122-0551	Applied twice daily for two weeks
DRUG	Vehicle	Applied twice daily for two weeks

Timeline

• Start date: 2012-05-01
• Primary completion: 2012-09-01
• Completion: 2013-03-01
• First posted: 2012-10-04
• Last updated: 2018-10-25
• Results posted: 2018-10-25

Locations

2 sites across 1 country: United States